Neurocrine Biosciences (NASDAQ:NBIX) had its target price lowered by analysts at ICAP from $140.00 to $128.00 in a research report issued on Tuesday, The Fly reports. The brokerage currently has an “outperform” rating on the stock. ICAP’s price objective points to a potential upside of 3.21% from the company’s previous close.
A number of other research analysts have also commented on NBIX. Cowen reiterated a “buy” rating and issued a $100.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, May 7th. BidaskClub upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, May 9th. Oppenheimer set a $120.00 price objective on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Monday, May 14th. ValuEngine upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Monday, May 14th. Finally, Barclays set a $100.00 price objective on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Friday, June 8th. Eighteen analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $120.47.
NASDAQ NBIX traded down $1.83 during trading hours on Tuesday, reaching $124.02. 1,493 shares of the company’s stock were exchanged, compared to its average volume of 550,824. The firm has a market cap of $11.12 billion, a PE ratio of -76.48, a price-to-earnings-growth ratio of 35.00 and a beta of 0.41. Neurocrine Biosciences has a one year low of $55.95 and a one year high of $126.28. The company has a debt-to-equity ratio of 1.00, a current ratio of 9.19 and a quick ratio of 9.19.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Tuesday, July 31st. The company reported ($0.07) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.11. The business had revenue of $96.90 million for the quarter, compared to analyst estimates of $84.11 million. Neurocrine Biosciences had a negative return on equity of 14.22% and a negative net margin of 16.07%. Neurocrine Biosciences’s revenue for the quarter was up 1428.4% on a year-over-year basis. During the same period in the prior year, the company earned ($0.68) EPS. equities analysts expect that Neurocrine Biosciences will post 0.17 earnings per share for the current year.
In other news, insider Dimitri E. Grigoriadis sold 23,022 shares of the stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $110.00, for a total value of $2,532,420.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Dimitri E. Grigoriadis sold 86,963 shares of the stock in a transaction on Thursday, June 14th. The shares were sold at an average price of $99.48, for a total value of $8,651,079.24. Following the completion of the transaction, the insider now directly owns 146,905 shares in the company, valued at approximately $14,614,109.40. The disclosure for this sale can be found here. In the last three months, insiders sold 157,985 shares of company stock worth $16,071,499. 4.30% of the stock is currently owned by company insiders.
Several hedge funds have recently bought and sold shares of NBIX. Global X Management Co. LLC lifted its stake in shares of Neurocrine Biosciences by 1,446.9% in the 1st quarter. Global X Management Co. LLC now owns 9,374 shares of the company’s stock valued at $777,000 after purchasing an additional 8,768 shares during the period. Oppenheimer & Co. Inc. acquired a new position in shares of Neurocrine Biosciences in the 1st quarter valued at $293,000. Trexquant Investment LP lifted its stake in shares of Neurocrine Biosciences by 935.6% in the 1st quarter. Trexquant Investment LP now owns 31,120 shares of the company’s stock valued at $2,581,000 after purchasing an additional 28,115 shares during the period. American Century Companies Inc. lifted its stake in shares of Neurocrine Biosciences by 1.3% in the 1st quarter. American Century Companies Inc. now owns 497,194 shares of the company’s stock valued at $41,232,000 after purchasing an additional 6,546 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in shares of Neurocrine Biosciences by 86,203.0% in the 1st quarter. Victory Capital Management Inc. now owns 569,600 shares of the company’s stock valued at $47,237,000 after purchasing an additional 568,940 shares during the period.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.
See Also: Asset Allocation and Your Retirement
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.